HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Halozyme Therapeutics (NASDAQ:HALO) and maintained a price target of $65.
August 08, 2024 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Halozyme Therapeutics and maintained a price target of $65.
The reiteration of a Buy rating and the maintenance of a $65 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100